ImmunoPrecise Antibodies Ltd.
IPA
$3.20
$0.5721.67%
NASDAQ
04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
---|---|---|---|---|---|
Net Income | -1.52M | -15.14M | -1.87M | -2.92M | -12.98M |
Total Depreciation and Amortization | 642.40K | 969.70K | 1.02M | 1.01M | 990.50K |
Total Amortization of Deferred Charges | 0.00 | 12.70K | 13.20K | 12.40K | 173.20K |
Total Other Non-Cash Items | 364.50K | 12.81M | -55.70K | -235.20K | 10.78M |
Change in Net Operating Assets | -288.50K | 508.80K | -753.60K | 804.80K | -128.20K |
Cash from Operations | -802.10K | -846.50K | -1.64M | -1.33M | -1.17M |
Capital Expenditure | -252.60K | -78.80K | -47.60K | -192.10K | -830.50K |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | 0.00 |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | 11.80K |
Cash from Investing | -252.60K | -78.80K | -47.60K | -192.10K | -818.80K |
Total Debt Issued | 0.00 | 183.00K | 1.46M | 2.60M | -- |
Total Debt Repaid | -435.00K | -341.00K | -407.00K | -394.00K | -302.00K |
Issuance of Common Stock | 17.00K | 10.70M | 1.02M | 491.00K | 1.43M |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -294.10K | 7.42M | 1.52M | 1.97M | 827.60K |
Foreign Exchange rate Adjustments | -209.00K | 107.70K | -102.50K | -112.50K | -865.90K |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -1.56M | 6.60M | -277.60K | 332.30K | -2.02M |